Colgate-Palmolive Co (CL) Stock News

Oriental Land has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The company is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential for near-term stock price appreciation. Analysts have raised consensus estimates by 10.9% over the past three months.

Celestica (CLS), an electronics manufacturing services company, has gained 9.6% over the past month, outperforming the S&P 500. The company shows strong earnings growth expectations of 87.1% year-over-year for the current fiscal year and 67.9% for the next fiscal year, with consistent revenue growth forecasts of 64.3% and 57.2% respectively. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term, and is valued at par with its peers.

Click Holdings Limited (NASDAQ: CLIK), a Hong Kong-based HR and senior care solutions company, highlighted a Morningstar report showing a quantitative fair value of $2.02 per share versus a last close of $1.09, representing a 46% discount. The company's book value yield ranks in the top 1% globally. However, Morningstar capped the rating at 3 stars due to very high uncertainty and potential value trap concerns. Click is expanding its Care U platform for senior nursing and rehabilitation services, targeting HK$500 million in annual revenue.

CleanSpark (CLSK) has underperformed the market, declining 13.3% over the past month. The company faces significant headwinds including a projected loss of $0.36 per share for the current quarter and a -683.1% year-over-year earnings change for the fiscal year. Revenue is expected to decline 41% in the current quarter and 23.8% for the fiscal year. The stock received a Zacks Rank #4 (Sell) rating and is trading at a premium valuation relative to peers, suggesting potential underperformance in the near term.

Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.

Cleveland-Cliffs stock declined 1.55% to $12.06, underperforming the S&P 500's 0.22% loss on October 7, 2026. The mining company is scheduled to report earnings on October 19, 2026, with forecasts showing EPS of $0.24 (up 153.33% YoY) and revenue of $5.58 billion (up 17.92% YoY). The stock holds a Zacks Rank #3 (Hold) rating, with consensus EPS projections rising 7.69% over the past 30 days.

EXCLUSIVE: Saudi Arabia launches air safety probe into flydubai incident, sources say  Reuters

EXCLUSIVE: Lebanon's Hezbollah gets $200 million from Iran to help displaced, sources say  Reuters

Girard Sharp LLP has filed a securities class action against Rocket Companies, Inc. following its October 2025 acquisition of Mr. Cooper Group. The complaint alleges that merger offering materials contained untrue statements and omitted material facts. Rocket shares have declined over 30% from the merger exchange price to below $12 per share by the time the lawsuit was filed.

Girard Sharp LLP has filed a securities class action against Blue Owl Technology Finance Corp. (OTF) alleging that merger offering materials contained untrue and misleading statements in connection with OTF's March 2025 acquisition of OTF II. Former OTF II investors who received OTF shares have experienced significant losses since the merger as OTF's share price has severely declined.

EXCLUSIVE: In interview, US Vice President Vance says Iran must cut nuclear enrichment to end war  Reuters

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

Norwegian Cruise Line (NCLH) fell 1.78% to $14.87, underperforming broader market gains. The stock has declined 2.76% over the past month. Upcoming earnings are projected to show a 26.67% year-over-year EPS decline to $0.88 per share, with revenue expected to drop 2.13%. NCLH holds a Zacks Rank of #5 (Strong Sell) with a Forward P/E of 9.73, trading at a discount to its industry average of 15.17.

A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements regarding adequate internal controls, understating regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresenting the company's business and prospects. Investors who purchased Anavex securities between November 26, 2025 and August 28, 2026 may be eligible to participate in the lawsuit.

India’s second-biggest state-owned refiner plans several funding tranches as it expands overseas energy investments and seeks to diversify supply

A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.

Remittix has confirmed November 24, 2026 as its RTX token launch date after raising over $32 million in presale funding. The PayFi platform is testing crypto-to-bank payments with 1,000 selected users. BNB is being analyzed for potential movement toward $1,000, while Hedera has contributed its Cross-Ledger Protocol (CLPR) to the Linux Foundation Decentralized Trust.

EXCLUSIVE: OPEC+ delays oil capacity review after Iran war disrupts expansion plans, sources say  Reuters

EXCLUSIVE: Europe weighs new diesel stocks release after US pressure, sources say  Reuters

EXCLUSIVE: US tells France and Germany to release diesel stocks or face US export ban, sources say  Reuters

Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.

EXCLUSIVE: US waives rights conditions for $320 million in military aid to Egypt, letter shows  Reuters

Norwegian Cruise Line Holdings (NCLH) has attracted significant investor attention but faces headwinds. The stock has declined 5.8% over the past month, underperforming the S&P 500. Earnings estimates for the current fiscal year show a -26.1% year-over-year decline, though next year is expected to grow 7.9%. The company received a Zacks Rank #5 (Strong Sell) rating, suggesting near-term underperformance relative to the broader market, despite trading at a valuation discount to peers.

EXCLUSIVE: Syrian government officials and Hezbollah held secret talks in Turkey, sources say  Reuters

NCL Corporation Ltd., a subsidiary of Norwegian Cruise Line Holdings, priced $950 million of 8.750% senior notes due 2031. The offering was increased from the initially announced $750 million. Proceeds will be used to redeem outstanding 2028 notes, repay revolving credit facility borrowings of $376.3 million, and prepay export-credit financing of $42.2 million. The offering is expected to close on October 15, 2026.

Carnival Corporation (CCL) reported Q3 2026 earnings that beat consensus estimates, with adjusted EPS of $1.43 vs. $1.36 expected and revenues of $8.44B vs. $8.36B. The company is about half-booked for 2027 with record occupancy and pricing above prior-year levels. CCL raised full-year constant-currency net yield growth guidance to 2.3%, up from June guidance. The company plans minimal 0.5% capacity growth in 2027 while shifting deployment toward higher-return destinations like Europe and private Caribbean islands. Management flagged Q1 2027 as different due to spring booking disruption but remains constructive on the rest of the year.

Royal Caribbean (RCL) is a trending stock with mixed performance. The cruise operator has underperformed the S&P 500 over the past month (-1.9% vs -0.4%) and its industry has declined 11%. However, earnings estimates show modest growth with current year EPS expected at $17.79 (+13.8% YoY) and next year at $20.11 (+13.1% YoY). Revenue is projected to grow 9.2% and 6.9% for the current and next fiscal years respectively. The stock holds a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

AB Discovery Growth A (CHCLX), a mid-cap growth mutual fund managed by AllianceBernstein, has received a Zacks Mutual Fund Rank of 1 (Strong Buy). However, the fund shows mixed performance metrics: weak 5-year returns (0.38%), higher volatility than peers, and negative alpha (-11.93%), indicating difficulty in outperforming benchmarks. Despite these concerns, its lower expense ratio (0.91%) and strong Zacks ranking suggest it may be worth considering for investors.

Carnival Corporation surged 13% after delivering better-than-expected Q3 results with record revenue of $8.44 billion and adjusted EPS of $1.43, beating consensus estimates. The company raised its 2026 outlook and reported record 2027 bookings, indicating strong cruise demand despite fuel cost pressures. However, analysts suggest investors may not need to aggressively chase the stock following the sharp rally, with a Zacks Rank #3 (Hold) rating.

Clean Harbors (CLH) is highlighted as an attractive growth stock with a Zacks Rank #2 (Buy) and Growth Score of B. The environmental services company demonstrates strong fundamentals including projected EPS growth of 33.6% (vs. 10.3% industry average), efficient asset utilization with an S/TA ratio of 0.82 (vs. 0.54 industry average), and positive earnings estimate revisions. Sales are expected to grow 7.7% this year compared to the industry average of 4.5%.